Acute promyelocytic leukemia (APL;FAB M3) has a balanced t(15;17)(q22;12-21) that rearranges theretinoic acid receptor? (RAR?) and promyelocytic leukemia (PML) genes. Two features distinguish APL: (1) APL cells express PML/RAR? resulting from this translocation and (2) all-trans-retinoic acid (RA)treatment of APL induces clinical remissions through successful differentiation therapy. Paradoxically, these responses are linked to expression of PML/RAR?, a dominant-negative transcription factor as our team and others reported. A hallmark of this APL differentiation program is the retinoid proteasomedependent degradation of PML/RAR?. The next challenge in achieving a molecular understanding of retinoid response in APL and other settings is to uncover retinoid target genes that directly regulate differentiation response. Microarray and biochemical analyses were successfully used in the prior funding period to discover the E1-like ubiquitin-activating enzyme, UBE1L, its ubiquitin-related partner, ISG15, and their deconjugase, UBP43, as previously unrecognized retinoid target genes constituting a novel pathway conferring PML/RAR? degradation. In this A2 revised competing renewal application of NIH RO1-CA062275-14 microarray analyses as well as unique cellular, biochemical and molecular genetic reagents are used to explore the novel retinoid target gene, G0S2, uncovered as one of the most prominent RAinduced species in APL and other cells. G0S2 serves an unexpected function as an inhibitor of retinoid response. Through three specific aims this proposal seeks to: (1) establish whether G0S2 is a direct retinoid target gene in APL cells and use proteomic and molecular pharmacology methods to learn if G0S2 phosphorylation directly affects its inhibition;(2) conduct gain and loss of function experiments to reveal how G0S2 regulates retinoid response in APL;and (3) establish in vivo relevancy by retinoid treatment of primary human APL cell cultures and in transgenic APL models. This proposal has implications beyond APL as G0S2 is retinoid induced in hematopoietic and non-hematopoietic tumor cells. Notably, sequence homology searches did not find homology between G0S2 and other species in the human database. Molecular pharmacologic approaches are used to achieve these aims, with unique biochemical, cellular, molecular genetic and transgenic models to probe comprehensively G0S2 function. This revised NIH R0-1 renewal application seeks to elucidate the precise role of G0S2 in RA differentiation response in APL. These findings are relevant to retinoid therapy of other human malignancies.

Public Health Relevance

All-trans-retinoic acid induces clinical remissions by causing differentiation of acute promyelocytic leukemia. A molecular understanding of how retinoic acid confers these effects is needed. This project studies a novel target gene called G0S2 that has been uncovered and regulates retinoic acid response. The mechanistic role of G0S2 in retinoic acid response will be elucidated in this proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA062275-17
Application #
8196951
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
1994-03-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
17
Fiscal Year
2012
Total Cost
$265,195
Indirect Cost
$99,344
Name
Dartmouth College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Uray, Iván P; Dmitrovsky, Ethan; Brown, Powel H (2016) Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Semin Oncol 43:49-64
Yim, Christina Y; Sekula, David J; Hever-Jardine, Mary P et al. (2016) G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. Cancer Res 76:1204-13
Chinyengetere, Fadzai; Sekula, David J; Lu, Yun et al. (2015) Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer 15:886
Liu, Xi; Gold, Kathryn A; Dmitrovsky, Ethan (2015) The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target. Mol Cancer Ther 14:1273-5
Gui, Jingang; Hu, Zhuting; Tsai, Ching-Yi et al. (2015) MCL1 enhances the survival of CD8+ memory T Cells after viral infection. J Virol 89:2405-14
Wei, Li-Na; Dmintrovsky, Ethan (2015) Retinoids are back. FASEB J 29:1131-5
Myung, Ja Hye; Roengvoraphoj, Monic; Tam, Kevin A et al. (2015) Effective capture of circulating tumor cells from a transgenic mouse lung cancer model using dendrimer surfaces immobilized with anti-EGFR. Anal Chem 87:10096-102
Ma, Tian; Lopez-Aguiar, Alexandra G N; Li, Aihua et al. (2014) Mice lacking G0S2 are lean and cold-tolerant. Cancer Biol Ther 15:643-50
Busch, Alexander M; Galimberti, Fabrizio; Nehls, Kristen E et al. (2014) All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biol Ther 15:463-72
Ma, Tian; Dong, Jessica P; Sekula, David J et al. (2013) Repression of exogenous gene expression by the retinoic acid target gene G0S2. Int J Oncol 42:1743-53

Showing the most recent 10 out of 47 publications